Aura Biosciences is a biotech company focused on developing therapies for cancer treatment. They use a virus-like drug conjugates (VDC) technology platform to target tumors in ocular and urologic oncology. Their main candidate, AU-011, is being developed for the treatment of primary choroidal melanoma and other ocular oncology indications. The company was founded in 2009 and is based in Cambridge, Massachusetts.